By now every Intuitive Surgical (NASDAQ:ISRG) investor is aware of "the report." Of course, that's a reference to the well-structured bear thesis laid out by Citron Research last month, clobbering shares of the medical robotics giant in the process.

Today, however, shareholders are marching to the beat of a different drum. After Intuitive far exceeded analyst expectations and issued equally strong guidance, Citron's stance is being rejected.

In this video, Motley Fool health care bureau chief Brenton Flynn takes a closer look at Citron's points in the context of this quarter's Intuitive Surgical earnings report, including one area where he and Citron tend to agree.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Intuitive Surgical. The Motley Fool owns shares of Intuitive Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.